Basilea Pharmaceutica (BSLN) Price & Analysis

Compare

4 Followers

BSLN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF37.50 - CHF59.70

Previous CloseN/A

Volume30.09K

Average Volume (3M)43.03K

Market Cap

CHF652.80M

Enterprise ValueCHF560.54M

Total Cash (Recent Filing)CHF120.71M

Total Debt (Recent Filing)CHF111.67M

Price to Earnings (P/E)8.4

Beta0.99

Next Earnings

Aug 19, 2025

EPS Estimate

2.03

Last Dividend Ex-Date

Apr 11, 2013

Dividend YieldN/A

Share Statistics

EPS (TTM)4.70

Shares Outstanding13,317,083

10 Day Avg. Volume48,415

30 Day Avg. Volume43,030

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF83.50

Price Target Upside55.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBasilea initiated a Phase 3 study for its antifungal fosmanogepix, showcasing its potential to treat invasive mold infections with a novel mechanism of action.

Product LaunchBasilea's antibiotic Zevtera is being launched in the U.S. ahead of schedule, offering potential for early revenue generation from royalties and sales milestones.

Sales MilestonesCresemba achieved a 20% year-over-year growth in global in-market sales, making it the largest branded antifungal for invasive fungal infections worldwide.

Bears Say

Clinical SetbacksSetbacks with clinical-stage candidates like fosmanogepix pose risks to Basilea's development pipeline.

Market PenetrationPotential challenges in achieving sufficient market penetration with ceftobiprole in the U.S. could impact revenue growth.

Partnership OptimizationInability by Basilea's partners to optimize the value of isavuconazole and ceftobiprole globally is a significant risk.

Basilea Pharmaceutica News

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

12h ago

Basilea Pharmaceutica Completes Phase 1 Study of Fosmanogepix: Implications for Investors

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

12h ago

Basilea’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer for Mold Infections

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

3d ago

Basilea Pharmaceutica’s Promising Future: Buy Rating Backed by Fosmanogepix Potential and Robust Valuation

Ram Selvaraju, an analyst from H.C. Wainwright, reiterated the Buy rating on Basilea Pharmaceutica. The associated price target...

5d ago

Basilea Pharmaceutica’s Fosmanogepix Study: A Potential Game-Changer in Antifungal Treatment

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

7d ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatments

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

10d ago

Basilea Pharmaceutica’s Fosmanogepix: A New Hope for Drug-Resistant Fungal Infections

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: The clinical...

16d ago

Basilea Pharmaceutica’s Phase 3 Trial: A Potential Game-Changer in Antifungal Treatment

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Study Overview: Basilea Pharmaceutica...

23d ago

Basilea Pharmaceutica’s Phase 3 Study on Fosmanogepix: A Potential Game-Changer in Antifungal Treatment

DEL_Basilea Pharmaceutica (($DEL_0QNA)), Basilea Pharmaceutica (($CH:BSLN)) announced an update on their ongoing clinical study. Basilea Pharmaceutica is conducting...

25d ago

Basilea Pharmaceutica Receives Buy Rating Backed by U.S. Government Funding and Promising Drug Developments

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Basilea Pharmaceutica, retaining the price target of...

1M ago

BSLN FAQ

What was Basilea Pharmaceutica’s price range in the past 12 months?

Basilea Pharmaceutica lowest stock price was CHF37.50 and its highest was CHF59.70 in the past 12 months.

What is Basilea Pharmaceutica’s market cap?

Basilea Pharmaceutica’s market cap is CHF652.80M.

When is Basilea Pharmaceutica’s upcoming earnings report date?

Basilea Pharmaceutica’s upcoming earnings report date is Aug 19, 2025 which is in 10 days.

How were Basilea Pharmaceutica’s earnings last quarter?

Basilea Pharmaceutica released its earnings results on Feb 18, 2025. The company reported CHF4.7 earnings per share for the quarter, beating the consensus estimate of CHF3.24 by CHF1.46.

Is Basilea Pharmaceutica overvalued?

According to Wall Street analysts Basilea Pharmaceutica’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Basilea Pharmaceutica pay dividends?

Basilea Pharmaceutica pays a Notavailable dividend of CHF5 which represents an annual dividend yield of N/A. See more information on Basilea Pharmaceutica dividends here

What is Basilea Pharmaceutica’s EPS estimate?

Basilea Pharmaceutica’s EPS estimate is 2.03.

How many shares outstanding does Basilea Pharmaceutica have?

Basilea Pharmaceutica has 13,317,083 shares outstanding.

What happened to Basilea Pharmaceutica’s price movement after its last earnings report?

Basilea Pharmaceutica reported an EPS of CHF4.7 in its last earnings report, beating expectations of CHF3.24. Following the earnings report the stock price went up 8.323%.

Which hedge fund is a major shareholder of Basilea Pharmaceutica?

Currently, no hedge funds are holding shares in CH:BSLN

Company Description

Basilea Pharmaceutica

Basilea Pharmaceutica (BSLN) is a Switzerland-based biopharmaceutical company focused on the research, development, and commercialization of innovative pharmaceutical products. The company operates primarily in the sectors of anti-infectives and oncology, offering solutions to address significant medical needs. Basilea's core products include novel antibiotics and antifungals for treating resistant bacterial and fungal infections, as well as targeted therapies for cancer treatment.

Basilea Pharmaceutica (BSLN) Earnings & Revenues

Historic Earnings Reports

BSLN Stock 12 Month Forecast

Average Price Target

CHF83.50

▲(55.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"CHF36","101":"CHF101","52.25":"CHF52.3","68.5":"CHF68.5","84.75":"CHF84.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF83.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF67.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,52.25,68.5,84.75,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,61.23076923076923,64.46153846153847,67.6923076923077,70.92307692307692,74.15384615384616,77.38461538461539,80.61538461538461,83.84615384615384,87.07692307692308,90.3076923076923,93.53846153846155,96.76923076923077,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,59.96153846153846,61.92307692307692,63.88461538461539,65.84615384615384,67.8076923076923,69.76923076923077,71.73076923076923,73.6923076923077,75.65384615384616,77.61538461538461,79.57692307692308,81.53846153846153,{"y":83.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,58,58.69230769230769,59.38461538461539,60.07692307692308,60.76923076923077,61.46153846153846,62.15384615384615,62.84615384615385,63.53846153846154,64.23076923076923,64.92307692307692,65.61538461538461,66.3076923076923,{"y":67,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.65,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.75,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.95,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.7,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >